 RBC Capital says Edgewise Therapeutics Incs NASDAQ: EWTX interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy BMD improve rewardrisk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD. 